CN108513587A - 对转移性疾病具有预测性的基因标签 - Google Patents

对转移性疾病具有预测性的基因标签 Download PDF

Info

Publication number
CN108513587A
CN108513587A CN201680045157.3A CN201680045157A CN108513587A CN 108513587 A CN108513587 A CN 108513587A CN 201680045157 A CN201680045157 A CN 201680045157A CN 108513587 A CN108513587 A CN 108513587A
Authority
CN
China
Prior art keywords
cancer
gene
prognosis
expression
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680045157.3A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·瓦尔克
劳拉·希尔
安德烈纳·麦卡维冈
西尼德·多尼根
提摩西·戴维森
理查德·肯内迪
丹尼斯·保罗·哈金
贝萨尼·普赖斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Al Mike Diagnostics Co Ltd
Original Assignee
Al Mike Diagnostics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Al Mike Diagnostics Co Ltd filed Critical Al Mike Diagnostics Co Ltd
Publication of CN108513587A publication Critical patent/CN108513587A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680045157.3A 2015-06-17 2016-06-17 对转移性疾病具有预测性的基因标签 Pending CN108513587A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1510684.2A GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease
GB1510684.2 2015-06-17
PCT/GB2016/051825 WO2016203262A2 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease

Publications (1)

Publication Number Publication Date
CN108513587A true CN108513587A (zh) 2018-09-07

Family

ID=53784091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680045157.3A Pending CN108513587A (zh) 2015-06-17 2016-06-17 对转移性疾病具有预测性的基因标签

Country Status (8)

Country Link
US (1) US20210254166A1 (https=)
EP (1) EP3310927B1 (https=)
JP (1) JP2018527886A (https=)
CN (1) CN108513587A (https=)
CA (1) CA2989388A1 (https=)
GB (1) GB201510684D0 (https=)
HK (1) HK1246367A1 (https=)
WO (1) WO2016203262A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120197220A (zh) * 2025-05-23 2025-06-24 华信咨询设计研究院有限公司 一种基于数据集中度的数据风险评估方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11341138B2 (en) * 2017-12-06 2022-05-24 International Business Machines Corporation Method and system for query performance prediction
GB201901439D0 (en) * 2019-02-01 2019-03-27 Univ London Method of predicting survival rates for cancer patients
GB201903014D0 (en) * 2019-03-06 2019-04-17 Univ Edinburgh Macrophage markers in cancer
GB201903015D0 (en) * 2019-03-08 2019-04-17 Univ Edinburgh Macrophage expression in breast cancer
US20210225460A1 (en) * 2020-01-21 2021-07-22 Genialis Inc. Evaluating the robustness and transferability of predictive signatures across molecular biomarker datasets
CA3174199A1 (en) 2020-04-09 2021-10-14 Ashraf Hafez Predicting likelihood and site of metastasis from patient records
BR112022024206A2 (pt) 2020-06-29 2023-01-03 Ionis Pharmaceuticals Inc Compostos e métodos para modular plp1
WO2022086914A1 (en) * 2020-10-19 2022-04-28 Temple University - Of The Commonwealth System Of Higher Education Genetic approach to suppress coronaviruses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471154A2 (en) * 2003-04-24 2004-10-27 Veridex LLC Breast cancer prognostics
WO2010068839A2 (en) * 2008-12-11 2010-06-17 The Regents Of The University Of California Membrane compositions and methods for making and using them
CN104603292A (zh) * 2012-07-20 2015-05-06 戴格努生命科学公司 用于提供前列腺癌的临床评估的方法、试剂盒和组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
CA1340843C (en) 1987-07-31 1999-12-07 J. Lawrence Burg Selective amplification of target polynucleotide sequences
CA2005589C (en) 1988-12-16 2001-02-06 Akzo Nobel Nv Self-sustained, sequence replication system
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
AU2002215345A1 (en) * 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
CA2519630A1 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
EP1815021A2 (en) 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
US20140018249A1 (en) * 2006-07-26 2014-01-16 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
US20090082218A1 (en) 2007-08-13 2009-03-26 Paul Harkin 3'-Based sequencing approach for microarray manufacture
US20120245235A1 (en) * 2009-12-01 2012-09-27 Compenda Bioscience, Inc Classification of cancers
CA2836277A1 (en) * 2011-05-17 2012-11-22 Takeda Pharmaceutical Company Limited Pharmaceutical compositions and methods for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471154A2 (en) * 2003-04-24 2004-10-27 Veridex LLC Breast cancer prognostics
WO2010068839A2 (en) * 2008-12-11 2010-06-17 The Regents Of The University Of California Membrane compositions and methods for making and using them
CN104603292A (zh) * 2012-07-20 2015-05-06 戴格努生命科学公司 用于提供前列腺癌的临床评估的方法、试剂盒和组合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120197220A (zh) * 2025-05-23 2025-06-24 华信咨询设计研究院有限公司 一种基于数据集中度的数据风险评估方法
CN120197220B (zh) * 2025-05-23 2025-08-01 华信咨询设计研究院有限公司 一种基于数据集中度的数据风险评估方法

Also Published As

Publication number Publication date
HK1246367A1 (zh) 2018-09-07
JP2018527886A (ja) 2018-09-27
CA2989388A1 (en) 2016-12-22
GB201510684D0 (en) 2015-08-05
EP3310927B1 (en) 2021-05-19
EP3310927A2 (en) 2018-04-25
US20210254166A1 (en) 2021-08-19
WO2016203262A2 (en) 2016-12-22
WO2016203262A3 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
Jiang et al. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment
US20220186311A1 (en) Methods for predicting anti-cancer response
AU2011302004B2 (en) Molecular diagnostic test for cancer
EP3080293B1 (en) Prostate cancer classification
EP3310927B1 (en) Gene signatures predictive of metastatic disease
Chen et al. Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance
US20130316931A1 (en) Markers of melanoma and uses thereof
JP2009528825A (ja) デュークスｂ大腸がんの再発を予測するための分子的解析
EP3119908A2 (en) Determining cancer aggressiveness, prognosis and responsiveness to treatment
JP7043404B2 (ja) 早期乳癌における内分泌処置後の残留リスクの遺伝子シグネチャー
US20090192045A1 (en) Molecular staging of stage ii and iii colon cancer and prognosis
Zhang et al. Profiling analysis of long non-coding RNA and mRNA in parathyroid carcinoma
Hwang et al. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer
Low et al. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer
WO2017046714A1 (en) Methylation signature in squamous cell carcinoma of head and neck (hnscc) and applications thereof
US20210310074A1 (en) Prognostic and predictive transcriptomic signatures for uterine serous carcinomas
WO2020104482A1 (en) Methods for predicting metastatic potential in patients suffering from sdhb-mutated paraganglioma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Craigavin, England

Applicant after: Almac Diagnostic Services Co.,Ltd.

Address before: Craigavin, England

Applicant before: ALMAC DIAGNOSTICS Ltd.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180907

WD01 Invention patent application deemed withdrawn after publication